In this paper, iRGD peptide-mediated quantum dots (QDs) delivery was studied. In the first step, dodecanethiol-capped CuInZnxS2+x (ZCIS) QDs were prepared and subsequently transferred into water using a standard and facile ligand exchange approach involving 3-mercaptopropionic acid (MPA). ZCIS@MPA nanocrystals possess a photoluminescence quantum yield (PL QY) of 25%, a PL emission centered at ca. 640nm and low distributions in size and shape. Next, the iRGD peptide was electrostatically associated to ZCIS@MPA QDs. After cytotoxicity evaluation, the tumor-targeting and penetrating activities of the iRGD/QD assembly were investigated by confocal microscopy. The experiments performed on various cancer cell lines revealed a high penetration ability of the assembly, while the bare QDs were not internalized. Additionally, imaging experiments were conducted on three-dimensional multicellular tumor spheroids in order to mimic the tumor microenvironment in vivo. iRGD/QD assemblies were found to be evenly distributed throughout the whole HeLa spheroid contrary to normal cells where they were not present. Therefore, iRGD/QD assemblies have a great potential to be used as targeted imaging agents and/or nanocarriers specific to cancer cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.colsurfb.2016.05.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer.
J Control Release
January 2025
Advanced Pharmaceutics and Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto M5S 3M2, Ontario, Canada. Electronic address:
Article Synopsis
- Metastatic breast cancer has a high mortality rate and is hard to treat, especially in triple-negative breast cancer (TNBC) due to factors like DNA repair and immunosuppression.
- PARP inhibitors like olaparib can help, but problems like drug resistance and increased PD-L1 can limit their effectiveness.
- The study tested a new treatment using specialized polymer-lipid nanoparticles carrying doxorubicin to target TNBC, showing better results in reducing tumor growth and metastasis compared to olaparib.
Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems.
Cancers (Basel)
November 2024
Department of Technology of Chemical Pharmaceutical and Cosmetic Products, D. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russia.
Chemotherapy remains the primary therapeutic approach in treating cancer. The tumor microenvironment (TME) is the complex network surrounding tumor cells, comprising various cell types, such as immune cells, fibroblasts, and endothelial cells, as well as ECM components, blood vessels, and signaling molecules. The often stiff and dense network of the TME interacts dynamically with tumor cells, influencing cancer growth, immune response, metastasis, and resistance to therapy.
View Article and Find Full Text PDFEnhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer.
Transl Lung Cancer Res
August 2024
Department of Thoracic Surgery, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: Accurate real-time tumor delineation is essential for achieving curative resection (R0 resection) during non-small cell lung cancer (NSCLC) surgery. The unique characteristics of lung tissue structure significantly challenge the use of video-assisted thoracoscopic surgery in the identification of lung nodules. This difficulty often results in an inability to discern the margins of lung nodules, necessitating either an expansion of the resection scope, or a transition to open surgery.
View Article and Find Full Text PDFiRGD-mediated liposomal nanoplatforms for improving hepatocellular carcinoma targeted combination immunotherapy and monitoring tumor response IVIM-MRI.
J Mater Chem B
October 2024
School of Medicine, South China University of Technology, Guangzhou, 510006, China.
Article Synopsis
- - The study explores a combination therapy for hepatocellular carcinoma (HCC) that uses targeted treatments and immune checkpoint blockade, specifically through a new nanodrug designed to improve drug delivery and reduce side effects.
- - Researchers developed iRGD-modified liposomal nanoparticles that co-encapsulate lenvatinib and a PD-1/PD-L1 inhibitor, enhancing drug accumulation in tumors and facilitating controlled release in acidic tumor environments.
- - IVIM-MRI technology was employed to non-invasively monitor treatment responses, highlighting changes in tumor blood vessel normalization and hypoxia, ultimately leading to improved antitumor effects and reduced metastasis in HCC cases.
iRGD-Guided Silica/Gold Nanoparticles for Efficient Tumor-Targeting and Enhancing Antitumor Efficacy Against Breast Cancer.
Int J Nanomedicine
August 2024
School of Pharmacy, Wannan Medical College, Wuhu, Anhui Province, People's Republic of China.
Background: Breast cancer presents significant challenges due to the limited effectiveness of available treatments and the high likelihood of recurrence. iRGD possesses both RGD sequence and C-terminal sequence and has dual functions of targeting and membrane penetration. iRGD-modified nanocarriers can enhance drug targeting of tumor vascular endothelial cells and penetration of new microvessels, increasing drug concentration in tumor tissues.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!